FMC and Corteva Strike $200M Deal to Expand Herbicide Access in Americas
Event summary
- FMC and Corteva signed a decade-long co-exclusive supply and license agreement for rimisoxafen herbicide technology in North and South America.
- Corteva will pay FMC $200 million upfront for the active ingredient, with both companies developing their own formulations.
- Rimisoxafen is classified as the industry's first dual mode of action herbicide, targeting resistant weeds like palmer amaranth.
- First commercial sales are expected by the end of the decade, pending regulatory approvals.
The big picture
This agreement underscores the growing collaboration between agricultural science companies to combat herbicide-resistant weeds, a critical challenge for global crop yields. The deal highlights the strategic importance of dual mode of action technologies in the crop protection sector, with both FMC and Corteva positioning themselves to capture significant market share in the Americas. The $200 million upfront payment also signals strong confidence in the commercial potential of rimisoxafen.
What we're watching
- Regulatory Approvals
- The pace at which rimisoxafen receives necessary regulatory approvals will determine the timeline for commercial sales and revenue realization.
- Market Adoption
- Whether growers will rapidly adopt rimisoxafen as a solution for herbicide-resistant weeds, particularly in key corn and soybean markets.
- Global Expansion
- How FMC's plans to develop additional rimisoxafen-based products for other crops and geographies will impact its long-term growth strategy.